What is NIMGenetics?
NIMGenetics operates as a specialized biomedical company dedicated to advanced clinical genetics. It offers a comprehensive suite of diagnostic services designed for healthcare professionals across various medical disciplines, including gynecology, pediatrics, neurology, and oncology. The company's core focus is on delivering high-quality, individualized genetic testing and support, with the ultimate goal of improving the health and quality of life for individuals affected by genetic disorders. NIMGenetics has established an international presence, serving markets in Spain, Portugal, Mexico, and the United States, demonstrating its global reach and commitment to advancing genetic diagnostics worldwide.
How much funding has NIMGenetics raised?
NIMGenetics has raised a total of $7.6M across 1 funding round:
Private Equity
$7.6M
Private Equity (2017): $7.6M with participation from Apposite Capital
Key Investors in NIMGenetics
Apposite Capital
Apposite Capital is a private equity firm with a specialized focus on the healthcare industry, particularly in lower mid-market investments across Europe. They are known for supporting healthcare SMEs through growth capital and strategic guidance to foster significant expansion and positive health outcomes.
What's next for NIMGenetics?
The recent major strategic investment in NIMGenetics signals a strong confidence in the company's growth trajectory and its capacity to innovate within the competitive biomedical landscape. This backing is likely to fuel further research and development, potentially leading to the introduction of new diagnostic tools and services. Furthermore, the capital infusion may support NIMGenetics' international expansion efforts, strengthening its market position in existing territories and enabling entry into new geographical regions. The company's focus on personalized genetic testing aligns with the growing trend towards precision medicine, positioning NIMGenetics for sustained growth and impact in improving patient care.
See full NIMGenetics company page
